Biogen (BIIB) Other Non Operating Income (2009 - 2015)
Biogen (BIIB) posted Other Non Operating Income of -$15.0 million for Q1 2015, down 70.88% on a QoQ basis from -$8.8 million in Q4 2014, and down 167.56% year-over-year from $22.2 million in Q1 2014.
Analysis
Biogen (BIIB) Other Non Operating Income (2009 - 2015) Analysis & Trends
Biogen has reported Other Non Operating Income for 7 years, with the latest figure at -$15.0 million in Q1 2015.
- On a quarterly basis, Other Non Operating Income fell 167.56% year-over-year to -$15.0 million in Q1 2015; TTM through Mar 2015 was -$35.2 million, a 35.1% decrease from a year earlier, with the FY2016 full-year figure at -$217.4 million, down 75.75% from the prior year.
- Other Non Operating Income was -$15.0 million for Q1 2015 at Biogen, down from -$8.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $15.1 million in Q1 2012, with the low at -$17.4 million in Q1 2011.
- Average Other Non Operating Income over 5 years is -$6.2 million, with a median of -$5.6 million recorded in 2014.
- The sharpest annual moves came in 2012 and 2013: Other Non Operating Income jumped 73850.0% in 2012, then tumbled 453.49% in 2013.
- Over 5 years, Other Non Operating Income stood at -$4.0 million in 2011, then plunged by 259.68% to -$14.3 million in 2012, then surged by 62.39% to -$5.4 million in 2013, then plunged by 63.16% to -$8.8 million in 2014, then slumped by 70.88% to -$15.0 million in 2015.
- The last three Other Non Operating Income figures came in at -$15.0 million (Q1 2015), -$8.8 million (Q4 2014), and -$16.3 million (Q3 2014), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2015 | -14.99 Mn |
| Dec 31, 2014 | -8.77 Mn |
| Sep 30, 2014 | -16.29 Mn |
| Jun 30, 2014 | 4.86 Mn |
| Mar 31, 2014 | -5.60 Mn |
| Dec 31, 2013 | -5.38 Mn |
| Sep 30, 2013 | -4.64 Mn |
| Jun 30, 2013 | -10.43 Mn |
| Mar 31, 2013 | -14.46 Mn |
| Dec 31, 2012 | -14.29 Mn |
| Sep 30, 2012 | -4.55 Mn |
| Jun 30, 2012 | 2.95 Mn |
| Mar 31, 2012 | 15.14 Mn |
| Dec 31, 2011 | -3.97 Mn |
| Sep 30, 2011 | -7.73 Mn |
| Jun 30, 2011 | -4,000.00 |
| Mar 31, 2011 | -17.38 Mn |
| Dec 31, 2010 | -4.70 Mn |
| Sep 30, 2010 | -6.90 Mn |
| Jun 30, 2010 | 1.00 Mn |